Trial · NCT01992653
Results by group270
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 270
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events in Diffuse Large B-Cell Lymphoma (DLBCL) Population | Polatuzumab Vedotin (1.0mg) + R-CHP | 2 | Participants | ||
| Number of Participants With Adverse Events in Diffuse Large B-Cell Lymphoma (DLBCL) Population | Polatuzumab Vedotin (1.4mg) + R-CHP | 3 | Participants | ||
| Number of Participants With Adverse Events in Diffuse Large B-Cell Lymphoma (DLBCL) Population | Polatuzumab Vedotin (1.8mg) + R-CHP | 5 | Participants | ||
| Number of Participants With Adverse Events in Diffuse Large B-Cell Lymphoma (DLBCL) Population | Polatuzumab Vedotin (2.4mg) + R-CHP | 0 | Participants | ||
| Number of Participants With Adverse Events in Diffuse Large B-Cell Lymphoma (DLBCL) Population | Polatuzumab Vedotin (1.4mg) + G-CHP | 4 | Participants | ||
| Number of Participants With Adverse Events in Diffuse Large B-Cell Lymphoma (DLBCL) Population | Polatuzumab Vedotin (1.8mg) + G-CHP | 4 | Participants | ||
| Number of Participants With Adverse Events in Diffuse Large B-Cell Lymphoma (DLBCL) Population | Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP | 40 | Participants | ||
| Number of Participants With Adverse Events in Diffuse Large B-Cell Lymphoma (DLBCL) Population | Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP | 17 | Participants | ||
| Number of Participants With Adverse Events in Non-DLBCL Population | Polatuzumab Vedotin (1.0mg) + R-CHP | 1 | Participants | ||
| Number of Participants With Adverse Events in Non-DLBCL Population | Polatuzumab Vedotin (1.4mg) + R-CHP | 0 | Participants | ||
| Number of Participants With Adverse Events in Non-DLBCL Population | Polatuzumab Vedotin (1.8mg) + R-CHP | 1 | Participants | ||
| Number of Participants With Adverse Events in Non-DLBCL Population | Polatuzumab Vedotin (2.4mg) + R-CHP | 1 | Participants | ||
| Number of Participants With Adverse Events in Non-DLBCL Population | Polatuzumab Vedotin (1.4mg) + G-CHP | 2 | Participants | ||
| Number of Participants With Adverse Events in Non-DLBCL Population | Polatuzumab Vedotin (1.8mg) + G-CHP | 2 | Participants | ||
| Number of Participants With Adverse Events in Non-DLBCL Population | Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP | 0 | Participants | ||
| Number of Participants With Adverse Events in Non-DLBCL Population | Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) in DLBCL Population | Polatuzumab Vedotin (1.0mg) + R-CHP | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) in DLBCL Population | Polatuzumab Vedotin (1.4mg) + R-CHP | 0 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) in DLBCL Population | Polatuzumab Vedotin (1.8mg) + R-CHP | 1 | Participants | ||
| Number of Participants With Dose Limiting Toxicities (DLTs) in DLBCL Population | Polatuzumab Vedotin (2.4mg) + R-CHP | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01992653/results